Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price & Analysis
Swedish Orphan Biovitrum AB (publ) (BIOVF) — price $47.35 (+10.37%), as of the Oct 5, 2026 trading session; market cap $16.4B. Expected results Oct 27, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Swedish Orphan Biovitrum AB (publ) · BIOVF · Healthcare · Medical - Pharmaceuticals
Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $47.35 | |
| Change on the day | +10.37% | |
| 52-week range | $30.05 – $49.03 | |
| Market capitalisation | $16.4B | |
| Price / earnings (trailing) | 107.76 | |
| Shares traded on the day | 200 | |
| Beta (volatility vs the S&P 500) | 0.29 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Now to add some color to this guidance upgrade related to revenue, we saw 26% growth at CER in H1, and we expect momentum to continue with ALTUVOCT, Doptelet, and Gamifant being the main growth drivers in full year 2026.
Henrik Stenqvist · Statement from
We will also have increased costs for the launch of Aspaveli nephrology as we continue the rollout in Europe, as well as in Tryngolza, where we will ensure a strong and well-prepared market entry to address the larger patient opportunity in sHTG, which we expect to launch next year.
Henrik Stenqvist · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Swedish Orphan Biovitrum AB (publ) (BIOVF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the BIOVF film — every key number, told as a short cinematic story
~2 min · open the film
What is Swedish Orphan Biovitrum AB (publ) (BIOVF), and what does it report?
Short answer · as of
Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Healthcare / Medical Pharmaceuticals Headquarters: Norra Stationsgatan 93A, Stockholm, 112 76, SE. It employs 1,888 people and is led by Guido Oelkers. In Q2 FY2026 it reported revenue of $778M and net income of $109M. The market values it at $16.4B.
What do the latest results show for Swedish Orphan Biovitrum AB (publ) (BIOVF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $778M. Against analyst estimates the company has EPS beat 6 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $805.37M Jul 16, 2026
- Latest report · revenue estimate
- $752.41M Jul 16, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 16, 2026
- Latest report · EPS vs estimate
- Below estimate Jul 16, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 16, 2026 | $805.37M | $752.41M | $0.3288 | $0.3800 |
| Apr 28, 2026 | $755.76M | $749.76M | $0.4500 | $0.3821 |
| Feb 5, 2026 | $846.23M | $863.40M | $0.6000 | $0.4567 |
| Oct 20, 2025 | $823.48M | $818.85M | −$0.8811 | $0.4925 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $778M | $109M | $0.31 (diluted) |
| Q1 FY2026 | $713M | $131M | $0.37 (diluted) |
| Q4 FY2025 | $774M | $184M | $0.53 (diluted) |
| Q3 FY2025 | $766M | -$285M | -$0.83 (diluted) |
What are the financial strengths and risks for Swedish Orphan Biovitrum AB (publ) (BIOVF)?
Short answer
The distress and quality screens read Altman Z 3.06 · Piotroski F 6. Trailing ratios: ROE 2.4% · ROA 1.1% · current ratio 0.70 · earnings yield 0.6% · free-cash-flow yield 4.4%.
What should you watch next at Swedish Orphan Biovitrum AB (publ) (BIOVF)?
Short answer · as of
The next earnings report is expected on Oct 27, 2026.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Now to add some color to this guidance upgrade related to revenue, we saw 26% growth at CER in H1, and we expect momentum to continue with ALTUVOCT, Doptelet, and Gamifant being the main growth drivers in full year 2026.
Henrik Stenqvist ·
We will also have increased costs for the launch of Aspaveli nephrology as we continue the rollout in Europe, as well as in Tryngolza, where we will ensure a strong and well-prepared market entry to address the larger patient opportunity in sHTG, which we expect to launch next year.
Henrik Stenqvist ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
What has been published about Swedish Orphan Biovitrum AB (publ) (BIOVF)?
BIOVF Healthcare Stock FAQ
These answers are editorial: 1 of these 8 answers is drawn from the BIOVF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is BIOVF a good stock to buy?
Stock Expert AI does not rate BIOVF buy, sell or hold. Swedish Orphan Biovitrum AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BIOVF stock price today?
The last price recorded on this page for Swedish Orphan Biovitrum AB (publ) (BIOVF) is $47.35, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the implications of BIOVF trading on the OTC market?
Trading on the OTC market, specifically the 'OTC Other' tier, carries several implications for BIOVF investors. This tier typically has less stringent listing and disclosure requirements compared to major exchanges like the NYSE or NASDAQ, which can lead to reduced transparency regarding financial reporting and corporate governance.
What are the key factors to evaluate for BIOVF?
Evaluate BIOVF on fundamentals, analyst consensus, and risk factors. P/E: 107.76x. Not financial advice.
How frequently does BIOVF data refresh on this page?
BIOVF's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BIOVF's recent stock price performance?
Swedish Orphan Biovitrum AB (publ) (BIOVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established portfolio of specialized drugs for rare diseases in hematology, immunology, and genetic/metabolic conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOVF overvalued or undervalued right now?
Swedish Orphan Biovitrum AB (publ) (BIOVF) trades at 107.76x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BIOVF before investing?
Before investing in Swedish Orphan Biovitrum AB (publ) (BIOVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (40 figures)
The 40 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Henrik Stenqvist (Jul 16, 2026): Now to add some color to this guidance upgrade related to revenue, we saw 26% growth at CER in H1, and we expect momentum to continue with ALTUVOCT, Doptelet, and Gamifant being the main growth drivers in full year 2026. Henrik Stenqvist (Jul 16, 2026): We will also have increased costs for the launch of Aspaveli nephrology as we continue the rollout in Europe, as well as in Tryngolza, where we will ensure a strong and well-prepared market entry to address the larger patient opportunity in sHTG, which we expect to launch next year. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 32 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $47.35 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:29.924Z. | |
px.change | Change on the day | +10.37% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $16.4B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T21:44:28.896Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Oct 27, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$4.45 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 107.76 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 200 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.29 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Pharmaceuticals | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Norra Stationsgatan 93A, Stockholm, 112 76, SE | FMP | Financial Modeling Prep (FMP) company profile — The FMP company description names Solna, Sweden as the headquarters; this page uses the address in this row. | |
id.employees | Employees | 1,888 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Guido Oelkers | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $778M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $109M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-16.revenue_actual | Revenue · reported — report date 2026-07-16 | $805.37M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-16.revenue_estimated | Revenue · estimate — report date 2026-07-16 | $752.41M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-16.eps_actual | EPS · reported — report date 2026-07-16 | $0.3288 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-16.eps_estimated | EPS · estimate — report date 2026-07-16 | $0.3800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.revenue_actual | Revenue · reported — report date 2026-04-28 | $755.76M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.revenue_estimated | Revenue · estimate — report date 2026-04-28 | $749.76M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.eps_actual | EPS · reported — report date 2026-04-28 | $0.4500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.eps_estimated | EPS · estimate — report date 2026-04-28 | $0.3821 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_actual | Revenue · reported — report date 2026-02-05 | $846.23M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_estimated | Revenue · estimate — report date 2026-02-05 | $863.40M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_actual | EPS · reported — report date 2026-02-05 | $0.6000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_estimated | EPS · estimate — report date 2026-02-05 | $0.4567 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-20.revenue_actual | Revenue · reported — report date 2025-10-20 | $823.48M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-20.revenue_estimated | Revenue · estimate — report date 2025-10-20 | $818.85M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-20.eps_actual | EPS · reported — report date 2025-10-20 | −$0.8811 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-20.eps_estimated | EPS · estimate — report date 2025-10-20 | $0.4925 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $30.05 – $49.03 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-30 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.06 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 2.4% · ROA 1.1% · current ratio 0.70 · earnings yield 0.6% · free-cash-flow yield 4.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-07-16.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($805.37M) with the recorded estimate ($752.41M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-16.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.3288) with the recorded estimate ($0.3800) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-16. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-16.revenue_actual,earn.history.depth.2026-07-16.revenue_estimated,earn.history.depth.2026-07-16.revenue_actual.comparison,earn.history.depth.2026-07-16.eps_actual.comparison,earn.history.depth.2026-07-16.eps_actual,earn.history.depth.2026-07-16.eps_estimated,earn.history.depth.2026-04-28.revenue_actual,earn.history.depth.2026-04-28.revenue_estimated,earn.history.depth.2026-04-28.eps_actual,earn.history.depth.2026-04-28.eps_estimated,earn.history.depth.2026-02-05.revenue_actual,earn.history.depth.2026-02-05.revenue_estimated,earn.history.depth.2026-02-05.eps_actual,earn.history.depth.2026-02-05.eps_estimated,earn.history.depth.2025-10-20.revenue_actual,earn.history.depth.2025-10-20.revenue_estimated,earn.history.depth.2025-10-20.eps_actual,earn.history.depth.2025-10-20.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.